Microbot Medical (NASDAQ:MBOT) Downgraded to Sell Rating by Wall Street Zen

Microbot Medical (NASDAQ:MBOT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

MBOT has been the topic of several other research reports. Zacks Research cut Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 21st. HC Wainwright boosted their price target on Microbot Medical from $9.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Microbot Medical Stock Up 3.2%

MBOT opened at $3.19 on Friday. Microbot Medical has a 52 week low of $0.85 and a 52 week high of $4.67. The business has a fifty day simple moving average of $3.20 and a 200-day simple moving average of $2.57. The firm has a market cap of $168.42 million, a P/E ratio of -5.50 and a beta of 1.22.

Microbot Medical (NASDAQ:MBOT) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Sell-side analysts expect that Microbot Medical will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Microbot Medical

Several institutional investors have recently added to or reduced their stakes in MBOT. XTX Topco Ltd bought a new position in shares of Microbot Medical in the second quarter worth about $43,000. American Century Companies Inc. bought a new position in shares of Microbot Medical in the second quarter worth about $32,000. DNB Asset Management AS raised its stake in shares of Microbot Medical by 67.9% in the second quarter. DNB Asset Management AS now owns 192,786 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 77,965 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Microbot Medical by 24.7% in the second quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 78,121 shares during the last quarter. Finally, Lazari Capital Management Inc. bought a new position in shares of Microbot Medical in the second quarter worth about $54,000. 16.30% of the stock is owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.